From the “AI Pilot Graveyard” to Enterprise- Grade Impact
Cloud-Native Drug Discovery
Relatively Speaking
Early-Phase Oncology Trials Shaping the Future of Cancer Research
Tailored Artificial Intelligence (AI)
EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
.webp)
KNOWLEDGE BANK
-
Articles
How AI Could Improve R&D Productivity Across the European Pharma Sector
Few industries invest in the future as heavily as European pharma According to the regions pharmaceutical industry federation the sector invested an estimated billion in research and development in Europe in making it the most researchintensive industry on the continent Yet boards increasingly confront an uncomfortable asymmetry Spending keeps climbing while the outputs that matter most
Fundamentals of Clinical Pharmacology: Understanding Drug Actions and Ensuring Safety
Clinical pharmacology offers the interface between the philosophies of pharmacology and its application in the actual sense in patient care Fundamentally it is the science which examines the activities of drugs how drugs communicate with biological systems and how such communications result in treatment outcomes or adverse events Clinical pharmacology principles are needed to make sense of how m...
Genetic Testing in Mainstream Medicine: Driving Precision, Prevention, and Population Health
Healthcare systems globally are shifting toward valuebased care where reimbursement is tied to outcomes not procedures Genetic testingparticularly multigene panels and polygenic risk scores is emerging as a highimpact enabler of early intervention and targeted prevention reducing longterm costs and improving clinical outcomes
The Permanent Prescription: Why Gene Therapy Is Rewriting the Rules of Drug Safety
Gene therapy has moved from laboratory promise to clinical reality offering something medicine has rarely been able to promise before a single treatment capable of curing a disease rather than merely managing it Yet this same quality of permanence is quietly undermining the safety systems the pharmaceutical industry has relied on for decades Adverse events can emerge a decade
Gene Therapy: Breakthrough Treatments for Rare Diseases
The idea of gene therapy is radically changing the sphere of medicine with the possibilities to cure the patients with the rare hereditary diseases These diseases which are usually brought about by the alteration of the sequence
Drug Safety in Focus: Challenges and Solutions for Pharma Companies
Drug safety is a paramount concern for pharmaceutical companies worldwide Ensuring the safety and efficacy of medications is not only a legal requirement but also a moral obligation towards patient welfare
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Fundamentals of Clinical Pharmacology: Understanding Drug Actions and Ensuring Safety
Kate Williamson
This article will discuss the fundamentals of clinical pharmacology, drug effects, pharmacodynamics and pharmacokinetics. It highlights evidence-based practice of drug safety, pharmacovigilance, and r...
-
2
Genetic Testing in Mainstream Medicine: Driving Precision, Prevention, and Population Health
Chandni Mansoori
Beyond rare disease diagnosis, the genetic testing is becoming a critical decision-making tool in the mainstream of medicine. This article will explore new opportunities to understand how genomic data...
-
3
The Permanent Prescription: Why Gene Therapy Is Rewriting the Rules of Drug Safety
John Praveen
Gene therapy is transforming medicine by offering the potential for one-time, curative treatments for previously untreatable genetic diseases. However, the very characteristic that makes these therapi...
-
4
Gene Therapy: Breakthrough Treatments for Rare Diseases
Kate Williamson
As a novel healing technique, gene therapy targets core issues in hereditary diseases. This is another approach where damaged genes are altered or removed; this has a ray of hope in diseases like SCID...
-
5
Drug Safety in Focus: Challenges and Solutions for Pharma Companies
Kate Williamson
Drug safety is crucial for pharmaceutical companies, involving challenges like adverse event monitoring, data management, regulatory compliance, and patient reporting. Solutions include advanced pharm...
press releases Read more...
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
NervGen NASDAQ NGEN a latestage clinical biopharmaceutical company developing firstinclass neuroreparative therapeutics for spinal cord injury SCI and other neurotraumatic and neurologic conditions today announced
Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease
Lineage Cell Therapeutics Inc NYSE American and TASE LCTX a clinicalstage biotechnology company developing allogeneic off the shelf cell therapies for serious medical conditions today announced that the Company has acquired NeuroAirmid
Instem and Sable Bio Launch Partnership to Accelerate Target Risk Assessment Through AI-Powered Scientific Intelligence
Instem a leading provider of software solutions and scientific services for drug discovery and development today announced a strategic partnership with Sable Bio to transform how biopharmaceutical organizations evaluate target safety and risk
Laboratoires Pierre Fabre and XtalPi Announce an AI-Driven Collaboration Focused on Drug Discovery
Laboratoires Pierre Fabre and XtalPi are pleased to announce an agreement under which they will collaborate on the discovery of novel clinical candidates across a number of research programs in the field of oncology potentially dermatology and rare diseases
Events Read more...
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
25 - 25
Nov 2026What’s Next for Pharma Marketing in 2027
Landesmuseum Zürich, Zurich, S...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
LATEST NEWS Read more...
Immuneering and Astellas to Evaluate Combination Treatments for CLDN18.2-Expressing Pancreatic Cancer
Immuneering Corporation Nasdaq IMRX has entered into a clinical trial collaboration and supply agreement with Astellas Pharma Global Development Inc a subsidiary of Astellas Pharma Inc TSE to evaluate combination treatments for patients with pancreatic cancer whose tumours express CLDN
Takeda Launches ORZEYFUL (Oveporexton), the First Orexin Agonist for Narcolepsy Type 1, in the US
Takeda TSE NYSE TAK has announced the US launch of ORZEYFUL oveporexton CIV now available by prescription for adults with narcolepsy type NT also known as narcolepsy with cataplexy The medicine is the first and only orexin agonist available for this condition
Applied Biologics Partners with Dartmouth College on Computational Protein Engineering Research
Applied Biologics a biopharmaceutical company developing biologic and gene therapies for serious diseases has entered into a research collaboration agreement with Dartmouth Colleges Thayer School of Engineering
Onco-Innovations Agrees to Terminate Performance-Based Funding Arrangement with Sorbie
OncoInnovations Limited Cboe ONCO has entered into an agreement with Sorbie Bornholm LP SBLP and Sorbie Investments LLP SILP to terminate its previously announced performancebased funding arrangement which was disclosed on July
Oncovita Granted Orphan Drug Designation For MVdeltaC in Mesothelioma by the European Commission
Oncovita a French biotechnology company specialized in therapeutic and prophylactic vaccines today announced that the European Commission has granted orphan medicinal product designation to its lead investigational candidate MVdeltaC for the treatment of mesothelioma
DeepLife and 3billion partner to discover small-molecule therapeutics against genetic modifier targets across multiple diseases
DeepLife a Parisbased techbio company developing AIpowered digital twins of human cells and billion an AIpowered genomics company specializing in rare disease diagnostics and drug discovery today announced a codevelopment collaboration to discover and develop new smallmolecule therapeutics
